CoChat
Cited by 15

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits

Ferranti, Anthony S., Foster, Daniel J. · 2022 · Frontiers in Neuroscience

Abstract

Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging evidence points to CB2 playing a key role in regulating neuronal function in the central nervous system. Recent anatomical studies, combined with electrophysiological studies, indicate that CB2 receptors are expressed in specific dopaminergic and glutamatergic brain circuits that are hyperactive in schizophrenia patients. The ability of CB2 receptors to inhibit dopaminergic and hippocampal circuits, combined with the anti-inflammatory effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia, a disease where novel interventions that move beyond dopamine receptor antagonists are desperately needed. The development of new CB2-related pharmacological and genetic tools, including the first small molecule positive allosteric modulator of CB2 receptors, has greatly advanced our understanding of this receptor. While more work is needed to further elucidate the translational value of selectively targeting CB2 receptors with respect to schizophrenia, the studies discussed below could suggest that CB2 receptors are anatomically located in schizophrenia-relevant circuits, where the physiological consequence of CB2 receptor activation could correct circuit-based deficits commonly associated with positive and cognitive deficits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2022.925792

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 116

  1. Aracil-Fernández, 2012, Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB2 receptors., Neuropsychopharmacology, 37, 1749, 10.1038/npp.2012.22 · DOI
  2. Ashton, 2006, Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study., Neurosci. Lett., 396, 113, 10.1016/j.neulet.2005.11.038 · DOI · Paper page
  3. Atwood, 2010, CB2: A cannabinoid receptor with an identity crisis., Br. J. Pharmacol., 160, 467, 10.1111/j.1476-5381.2010.00729.x · DOI · Paper page
  4. Beltramo, 2009, Cannabinoid type 2 receptor as a target for chronic - pain., Mini Rev. Med. Chem., 9, 11, 10.2174/138955709787001785 · DOI
  5. Bian, 2022, Artificial Intelligent deep learning molecular generative modeling of scaffold-focused and cannabinoid CB2 target-specific small-molecule sublibraries., Cells, 11, 10.3390/cells11050915 · DOI
  6. Boggs, 2018, The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial., Psychopharmacology, 235, 1923, 10.1007/s00213-018-4885-9 · DOI · Paper page
  7. Bouchard, 2012, Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington’s disease., J. Neurosci., 32, 18259, 10.1523/JNEUROSCI.4008-12.2012 · DOI
  8. Brown, 2002, Cloning and molecular characterization of the rat CB2 cannabinoid receptor., Biochim. Biophys. Acta, 1576, 255, 10.1016/S0167-4781(02)00341-X · DOI · Paper page
  9. Brusco, Ultrastructural localization of neuronal brain CB2 cannabinoid receptors., Ann. N.Y.Acad. Sci., 1139, 450, 10.1196/annals.1432.037 · DOI · Paper page
  10. Brusco, Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus., Synapse, 62, 944, 10.1002/syn.20569 · DOI · Paper page
  11. Buckley, 2008, The peripheral cannabinoid receptor knockout mice: An update., Br. J. Pharmacol., 153, 309, 10.1038/sj.bjp.0707527 · DOI
  12. Busquets-Garcia, 2017, Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice., Mol. Psychiatry, 22, 1594, 10.1038/mp.2017.4 · DOI
  13. Byun, 2014, Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100., Neuropsychopharmacology, 39, 1578, 10.1038/npp.2014.2 · DOI
  14. Cabanero, 2020, Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain., Elife, 9, 255, 10.7554/eLife.55582 · DOI
  15. Canseco-Alba, 2021, Cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons induced hyperactivity phenotype: Possible relevance to attention-deficit hyperactivity disorder., Front. Psychiatry, 12, 10.3389/fpsyt.2021.803394 · DOI
  16. Canseco-Alba, 2019, Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons., Behav. Brain Res., 360, 286, 10.1016/j.bbr.2018.11.043 · DOI
  17. de Oliveira, 2022, CB2 and toll-like receptors crosstalk in microglia., Trends Neurosci., 45, 1, 10.1016/j.tins.2021.10.012 · DOI
  18. Delis, 2017, Attenuation of cocaine-induced conditioned place preference and motor activity via cannabinoid CB2 receptor agonism and CB1 receptor antagonism in rats., Int. J. Neuropsychopharmacol., 20, 269, 10.1093/ijnp/pyw102 · DOI
  19. den Boon, 2014, Endocannabinoids produced upon action potential firing evoke a Cl- current via type-2 cannabinoid receptors in the medial prefrontal cortex., Pflügers Archiv., 466, 2257, 10.1007/s00424-014-1502-6 · DOI
  20. den Boon, 2012, Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors., Proc. Natl. Acad. Sci. U.S.A., 109, 3534, 10.1073/pnas.1118167109 · DOI · Paper page
  21. Dhopeshwarkar, 2016, Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway., J. Pharmacol. Exp. Ther., 358, 342, 10.1124/jpet.116.232561 · DOI
  22. Di Forti, 2014, Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users., Schizophr. Bull., 40, 1509, 10.1093/schbul/sbt181 · DOI · Paper page
  23. Di Marzo, 2018, New approaches and challenges to targeting the endocannabinoid system., Nat. Rev. Drug Discov., 17, 623, 10.1038/nrd.2018.115 · DOI · Paper page
  24. Dogra, 2021, Activating mGlu3 metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus., Biol. Psychiatry, 90, 385, 10.1016/j.biopsych.2021.02.970 · DOI
  25. Dong, 2021, A fluorescent sensor for spatiotemporally resolved imaging of endocannabinoid dynamics in vivo., Nat. Biotechnol., 40, 787, 10.1038/s41587-021-01074-4 · DOI · Paper page
  26. D’Souza, 2004, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis., Neuropsychopharmacology, 29, 1558, 10.1038/sj.npp.1300496 · DOI · Paper page
  27. Duffy, 2021, The cannabinoid system and microglia in health and disease., Neuropharmacology, 190, 10.1016/j.neuropharm.2021.108555 · DOI · Paper page
  28. Foster, 2017, Allosteric modulation of GPCRs: New insights and potential utility for treatment of schizophrenia and other CNS disorders., Neuron, 94, 431, 10.1016/j.neuron.2017.03.016 · DOI · Paper page
  29. Foster, 2016, Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release., Neuron, 91, 1244, 10.1016/j.neuron.2016.08.017 · DOI
  30. Gado, 2019, Identification of the first synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief., J. Med. Chem., 62, 276, 10.1021/acs.jmedchem.8b00368 · DOI
  31. Gado, 2022, Design, synthesis, and biological activity of new CB2 receptor ligands: From orthosteric and allosteric modulators to dualsteric/bitopic ligands., J. Med. Chem., 65, 9918, 10.1021/acs.jmedchem.2c00582 · DOI
  32. Galaj, 2020, Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT(1A) and TRPV1 receptor mechanisms., Neuropharmacology, 167, 10.1016/j.neuropharm.2019.107740 · DOI
  33. Galiègue, 1995, Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations., Eur. J. Biochem., 232, 54, 10.1111/j.1432-1033.1995.tb20780.x · DOI · Paper page
  34. Gantz, 2017, Cell-autonomous excitation of midbrain dopamine neurons by endocannabinoid-dependent lipid signaling., Neuron, 93, 1375.e, 10.1016/j.neuron.2017.02.025 · DOI
  35. García-Gutiérrez, 2018, Alterations in gene and protein expression of cannabinoid CB2 and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims., Neurotherapeutics, 15, 796, 10.1007/s13311-018-0610-y · DOI
  36. García-Gutiérrez, 2013, Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors., Neuropharmacology, 73, 388, 10.1016/j.neuropharm.2013.05.034 · DOI
  37. Giuffrida, 2004, Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms., Neuropsychopharmacology, 29, 2108, 10.1038/sj.npp.1300558 · DOI · Paper page
  38. Gong, 2006, Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain., Brain Res., 1071, 10, 10.1016/j.brainres.2005.11.035 · DOI · Paper page
  39. Hallak, 2010, Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD)., Braz. J. Psychiatry, 32, 56, 10.1590/s1516-44462010000100011 · DOI
  40. Han, 2014, Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor., Mini Rev. Med. Chem., 14, 426, 10.2174/1389557514666140428105753 · DOI
  41. Hanus, 1999, HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor., Proc. Natl. Acad. Sci. U.S.A., 96, 14228, 10.1073/pnas.96.25.14228 · DOI · Paper page
  42. Howes, 2009, The dopamine hypothesis of schizophrenia: Version III–the final common pathway., Schizophr. Bull., 35, 549, 10.1093/schbul/sbp006 · DOI · Paper page
  43. Howlett, 2002, International union of pharmacology. XXVII. classification of cannabinoid receptors., Pharmacol. Rev., 54, 161, 10.1124/pr.54.2.161 · DOI · Paper page
  44. Hua, 2020, Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures., Cell, 180, 655, 10.1016/j.cell.2020.01.008 · DOI · Paper page
  45. Incontro, 2021, Endocannabinoids tune intrinsic excitability in O-LM interneurons by direct modulation of postsynaptic Kv7 channels., J. Neurosci., 41, 9521, 10.1523/jneurosci.1279-21.2021 · DOI
  46. Ishiguro, 2010, Brain cannabinoid CB2 receptor in schizophrenia., Biol. Psychiatry, 67, 974, 10.1016/j.biopsych.2009.09.024 · DOI · Paper page
  47. Ji, 2021, The CB2 receptor as a novel therapeutic target for epilepsy treatment., Int. J. Mol. Sci., 22, 10.3390/ijms22168961 · DOI
  48. Jordan, 2020, Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents., Neuropharmacology, 176, 108241, 10.1016/j.neuropharm.2020.108241 · DOI
  49. Kano, 2009, Endocannabinoid-mediated control of synaptic transmission., Physiol. Rev., 89, 309, 10.1152/physrev.00019.2008 · DOI · Paper page
  50. Khella, 2014, CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice., Psychopharmacology, 231, 3071, 10.1007/s00213-014-3481-x · DOI
  51. Kim, 2015, Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission., J. Physiol., 593, 871, 10.1113/jphysiol.2014.286633 · DOI
  52. Kohler-Forsberg, 2020, Editorial: The role of inflammation in the etiology and treatment of schizophrenia., Front. Psychiatry, 11, 10.3389/fpsyt.2020.603296 · DOI
  53. Komorowska-Müller, 2020, CB2 receptor in microglia: The guardian of self-control., Int. J. Mol. Sci., 22, 10.3390/ijms22010019 · DOI · Paper page
  54. Komorowska-Müller, Cannabinoid receptor 2 alters social memory and microglial activity in an age-dependent manner., Molecules, 26, 10.3390/molecules26195984 · DOI
  55. Komorowska-Müller, Cannabinoid receptor 2 deletion influences social memory and synaptic architecture in the hippocampus., Sci. Rep., 11, 16828, 10.1038/s41598-021-96285-9 · DOI
  56. Lan, 1999, Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand., AAPS PharmSci, 1, 10.1208/ps010204 · DOI
  57. Lanciego, 2011, Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis., J. Psychopharmacol., 25, 97, 10.1177/0269881110367732 · DOI
  58. Legge, 2019, Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits., JAMA Psychiatry, 76, 1256, 10.1001/jamapsychiatry.2019.2508 · DOI
  59. Li, 2021, Cannabinoid receptor 2 deficiency enhances isoflurane-induced spatial cognitive impairment in adult mice by affecting neuroinflammation, neurogenesis and neuroplasticity., Exp. Ther. Med., 22, 908, 10.3892/etm.2021.10340 · DOI
  60. Li, 2015, Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus., Neuroscience, 311, 253, 10.1016/j.neuroscience.2015.10.041 · DOI
  61. Li, CB2 cannabinoid receptor knockout in mice impairs contextual long-term memory and enhances spatial working memory., Neural Plast., 2016, 10.1155/2016/9817089 · DOI
  62. Li, Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus., Hippocampus, 26, 275, 10.1002/hipo.22558 · DOI
  63. Li, 2017, Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus., Neuroscience, 363, 11, 10.1016/j.neuroscience.2017.08.053 · DOI
  64. Lieberman, 2018, Hippocampal dysfunction in the pathophysiology of schizophrenia: A selective review and hypothesis for early detection and intervention., Mol. Psychiatry, 23, 1764, 10.1038/mp.2017.249 · DOI · Paper page
  65. Lin, 2021, A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: Evidence from a CB2: Reporter mouse., PAIN, 163, 834, 10.1097/j.pain.0000000000002502 · DOI
  66. Liu, 2017, Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference., Sci. Rep., 7, 10.1038/s41598-017-17796-y · DOI · Paper page
  67. Lopes, 2020, The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice., Psychopharmacology, 237, 385, 10.1007/s00213-019-05370-5 · DOI
  68. López-Ramírez, 2020, D2autoreceptor switches CB2receptor effects on [3H]-dopamine release in the striatum., Synapse, 74, 10.1002/syn.22139 · DOI
  69. Lu, 2021, Review of the endocannabinoid system., Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 6, 607, 10.1016/j.bpsc.2020.07.016 · DOI · Paper page
  70. Manzanares, 2018, Role of the endocannabinoid system in drug addiction., Biochem. Pharmacol., 157, 108, 10.1016/j.bcp.2018.09.013 · DOI
  71. McCoy, 1999, Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation., J. Pharmacol. Exp. Ther., 289, 1620
  72. McGuire, 2018, Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled Trial., Am. J. Psychiatry, 175, 225, 10.1176/appi.ajp.2017.17030325 · DOI · Paper page
  73. Minichino, 2019, Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis., JAMA Psychiatry, 76, 914, 10.1001/jamapsychiatry.2019.0970 · DOI
  74. Miranzadeh Mahabadi, 2021, Cannabinoid receptors distribution in mouse cortical plasma membrane compartments., Mol. Brain, 14, 10.1186/s13041-021-00801-x · DOI
  75. Monory, 2007, Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice., PLoS Biol., 5, 10.1371/journal.pbio.0050269 · DOI · Paper page
  76. Morales, 2016, Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update., Expert. Opin. Ther. Pat., 26, 843, 10.1080/13543776.2016.1193157 · DOI
  77. Morgan, 2008, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis., Br. J. Psychiatry, 192, 306, 10.1192/bjp.bp.107.046649 · DOI · Paper page
  78. Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids., Nature, 365, 61, 10.1038/365061a0 · DOI · Paper page
  79. Murineddu, 2013, Different classes of CB2 ligands potentially useful in the treatment of pain., Recent Pat. CNS Drug Discov., 8, 42, 10.2174/15748898112079990016 · DOI
  80. Navarrete, 2021, CB2 receptor involvement in the treatment of substance use disorders., Biomolecules, 11, 10.3390/biom11111556 · DOI
  81. Navarro, 2021, Design of negative and positive allosteric modulators of the cannabinoid CB2 receptor derived from the natural product cannabidiol., J. Med. Chem., 64, 9354, 10.1021/acs.jmedchem.1c00561 · DOI
  82. Onaivi, 2006, Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain., Neuropsychobiology, 54, 231, 10.1159/000100778 · DOI · Paper page
  83. Onaivi, 2006, Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain., Ann. N.Y . Acad. Sci., 1074, 514, 10.1196/annals.1369.052 · DOI · Paper page
  84. Ortega-Alvaro, 2011, Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice., Neuropsychopharmacology, 36, 1489, 10.1038/npp.2011.34 · DOI · Paper page
  85. Pacher, 2006, The endocannabinoid system as an emerging target of pharmacotherapy., Pharmacol. Rev., 58, 389, 10.1124/pr.58.3.2 · DOI · Paper page
  86. Pertwee, 2008, Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond., Addict. Biol., 13, 147, 10.1111/j.1369-1600.2008.00108.x · DOI · Paper page
  87. Pertwee, 2010, International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2)., Pharmacol. Rev., 62, 588, 10.1124/pr.110.003004 · DOI · Paper page
  88. Petrucci, 2017, Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage., Sci. Rep., 7, 10.1038/s41598-017-09808-8 · DOI
  89. Polini, 2020, Positive allosteric modulation of CB1 and CB2 cannabinoid receptors enhances the neuroprotective activity of a dual CB1R/CB2R orthosteric agonist., Life, 10, 10.3390/life10120333 · DOI
  90. Reusch, 2022, Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation., Glia, 70, 71, 10.1002/glia.24089 · DOI
  91. Rinaldi-Carmona, 1998, SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor., J. Pharmacol. Exp. Ther., 284, 644
  92. Rivas-Santisteban, 2021, N-Methyl-D-aspartate (n.d.) and cannabinoid CB(2) receptors form functional complexes in cells of the central nervous system: Insights into the therapeutic potential of neuronal and microglial NMDA receptors., Alzheimer’s Res. Ther., 13, 184, 10.1186/s13195-021-00920-6 · DOI
  93. Rodrigues da Silva, 2020, Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors., Pharmacol. Res., 156, 10.1016/j.phrs.2020.104749 · DOI
  94. Ross, 1999, Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633. L759656, and AM630., Br. J. Pharmacol., 126, 665, 10.1038/sj.bjp.0702351 · DOI · Paper page
  95. Sagar, 2005, Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats., Eur. J. Neurosci., 22, 371, 10.1111/j.1460-9568.2005.04206.x · DOI
  96. Schatz, 1997, Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system., Toxicol. Appl. Pharmacol., 142, 278, 10.1006/taap.1996.8034 · DOI · Paper page
  97. Shapiro, 2021, Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice., Neuropharmacology, 188, 10.1016/j.neuropharm.2021.108448 · DOI
  98. Soethoudt, 2017, Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity., Nat. Commun., 8, 10.1038/ncomms13958 · DOI · Paper page
  99. Stansley, 2018, The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia., Curr. Opin. Pharmacol., 38, 31, 10.1016/j.coph.2018.02.003 · DOI
  100. Stempel, 2016, Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus., Neuron, 90, 795, 10.1016/j.neuron.2016.03.034 · DOI · Paper page
  101. Sun, 2017, Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity., J. Neuroinflamm., 14, 138, 10.1186/s12974-017-0913-7 · DOI
  102. Thakur, 2009, Latest advances in cannabinoid receptor agonists., Exp. Opin. Ther. Pat., 19, 1647, 10.1517/13543770903436505 · DOI
  103. Tham, 2019, Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors., Br. J. Pharmacol., 176, 1455, 10.1111/bph.14440 · DOI · Paper page
  104. Tsou, 1998, Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system., Neuroscience, 83, 393, 10.1016/S0306-4522(97)00436-3 · DOI · Paper page
  105. Van Sickle, 2005, Identification and functional characterization of brainstem cannabinoid CB2 receptors., Science, 310, 329, 10.1126/science.1115740 · DOI · Paper page
  106. Volk, 2016, The role of endocannabinoid signaling in cortical inhibitory neuron dysfunction in schizophrenia., Biol. Psychiatry, 79, 595, 10.1016/j.biopsych.2015.06.015 · DOI
  107. Volk, 2010, Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia., Am. J. Psychiatry, 167, 1489, 10.1176/appi.ajp.2010.10030318 · DOI
  108. Wootten, 2018, Mechanisms of signalling and biased agonism in G protein-coupled receptors., Nat. Rev. Mol. Cell Biol., 19, 638, 10.1038/s41580-018-0049-3 · DOI · Paper page
  109. Wu, 2013, Activation of the CB2 receptor system reverses amyloid-induced memory deficiency., Neurobiology of Aging, 34, 791, 10.1016/j.neurobiolaging.2012.06.011 · DOI · Paper page
  110. Xing, 2020, Cryo-EM Structure of the human cannabinoid receptor CB2-G(i) signaling complex., Cell, 180, 645.e, 10.1016/j.cell.2020.01.007 · DOI · Paper page
  111. Yuan, 2022, In silico prediction and validation of CB2 allosteric binding sites to aid the design of allosteric modulators., Molecules, 27, 10.3390/molecules27020453 · DOI
  112. Zhang, 2021, Cannabidiol inhibition of murine primary nociceptors: Tight binding to slow inactivated states of Na(v)1.8 channels., J. Neurosci., 41, 6371, 10.1523/jneurosci.3216-20.2021 · DOI
  113. Zhang, Repeated cocaine administration upregulates CB(2) receptor expression in striatal medium-spiny neurons that express dopamine D(1) receptors in mice., Acta Pharmacol. Sin., 43, 876, 10.1038/s41401-021-00712-6 · DOI
  114. Zhang, 2015, Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats., Neuropsychopharmacology, 40, 1037, 10.1038/npp.2014.297 · DOI
  115. Zhang, 2017, Expression of functional cannabinoid CB(2) receptor in VTA dopamine neurons in rats., Addic. Biol., 22, 752, 10.1111/adb.12367 · DOI
  116. Zhang, Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice., Neuropharmacology, 189, 10.1016/j.neuropharm.2021.108538 · DOI

Cited by

See all 15

Metadata

Authors
Ferranti, A. S., & Foster, D. J.
Venue
Frontiers in Neuroscience
Published
2022-08-11
Volume
16
ISSN
1662-453X
Cited by
15
References
10

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. https://app.cochat.ai/papers/10.3389/fnins.2022.925792
The paper
Ferranti, A. S., & Foster, D. J. (2022). Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2022.925792

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.